The Most Hated High Yields On Wall Street
Let's capitalize on analyst incompetence—and bank yields up to 18.3%, with upside to boot!
ALX - Alexander's, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$125.00
DETAILS
HIGH:
$125.00
LOW:
$125.00
MEDIAN:
$125.00
CONSENSUS:
$125.00
DOWNSIDE:
49.23%
Stock News
First Look: Aramco profit jump, Nvidia-Corning deal, GM fined
Stock News Discount chains gain share: Budget-conscious consumers are flocking to discounters, with Aldi adding 17 million U.S. customers in 2025 and planning 1
ALX Oncology Q1 Earnings Call Highlights
ALX Oncology NASDAQ: ALXO executives used the company's first-quarter 2026 earnings call to highlight new clinical data for its lead CD47 blocker, evorpacept, and to provide updates on its EGFR-targeted antibody-drug conjugate program, ALX2004. CEO Jason Lettmann said the quarter featured “continued good execution,” including a February financing and the addition of Jeff Knight as chief development and chief operating officer.
ALX Oncology Reports First Quarter 2026 Financial Results and Provides Corporate Update
- Data from Phase 1b/2 trial of evorpacept + zanidatamab presented at ESMO Breast Cancer 2026 showed all patients with confirmed HER2-positive disease and high CD47 expression experienced durable responses to this combination -
ALX Oncology's Evorpacept in Combination with Zanidatamab Generates Promising, Durable Response in Patients with Advanced HER2-Positive Breast Cancer and High CD47 Expression
- Data from Phase 1b/2 trial presented at ESMO Breast Cancer 2026 further validate a biomarker-driven development strategy for evorpacept -
Alexander's (ALX) Q1 FFO and Revenues Lag Estimates
Alexander's (ALX) came out with quarterly funds from operations (FFO) of $2.6 per share, missing the Zacks Consensus Estimate of $3.08 per share. This compares to FFO of $4.06 per share a year ago.
A Look at Alexander's Inc (ALX) After 3.0% Decline -- GF Value $203.84 vs Price $244.34
On May 01, 2026, Alexander's Inc (ALX) shares fell 3.0%, closing at $244.34. The stock has traded within a 52-week range of $201.28 to $260.84, reflecting some
ALX Oncology Announces That CD47 Biomarker Data from Clinical Trial Evaluating Evorpacept + Zanidatamab Combination in Advanced Breast Cancer Will Be Presented at ESMO Breast Cancer 2026
- Company Will Discuss Data and Report First Quarter 2026 Financial Results on May 8 - SOUTH SAN FRANCISCO, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology"; Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, today announced that new data from the Phase 1b/2 clinical trial evaluating the company's investigational CD47-inhibitor evorpacept in combination with Jazz Pharmaceuticals' zanidatamab (ZIIHERA®) in heavily pretreated patients with HER2-positive metastatic breast cancer (mBC) will be presented at the ESMO Breast Cancer 2026 Congress in Berlin on May 7.
Alexander's Declares Quarterly $4.50 Dividend on Common Shares
PARAMUS, N.J., April 29, 2026 (GLOBE NEWSWIRE) -- Alexander's, Inc. (NYSE: ALX) today announced that its Board of Directors has declared a regular quarterly dividend of $4.50 per share payable on May 29, 2026 to stockholders of record on May 11, 2026.
Alexander's Announces First Quarter Earnings Release Date and Vornado Realty Trust Quarterly Conference Call
PARAMUS, N.J., April 21, 2026 (GLOBE NEWSWIRE) -- Alexander's, Inc. (NYSE: ALX) today announced that it will file its quarterly report on Form 10-Q for the quarter ended March 31, 2026 with the U.S. Securities and Exchange Commission and issue its first quarter earnings release on Monday, May 4, 2026, before the New York Stock Exchange opens.
ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules
SOUTH SAN FRANCISCO, Calif., April 17, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (“ALX Oncology,” Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, announced that the Compensation Committee of the Board of Directors of ALX Oncology approved the granting of an inducement stock option to purchase a total of 800,000 shares of ALX Oncology's common stock to Jeff Knight, M.P.H., Chief Development and Operating Officer, on April 16, 2026 in connection with the commencement of his employment. Mr. Knight's inducement stock option is subject to the terms of the ALX Oncology Holdings Inc. 2025 Inducement Equity Incentive Plan and related forms of agreements, and was granted as an inducement material to Mr. Knight to enter into employment with ALX Oncology in accordance with Nasdaq Listing Rule 5635(c)(4).
Longleaf Partners Small-Cap Fund Q1 2026 Portfolio Review
Alcoholic beverage company Boston Beer was a contributor for the quarter as industry data improved compared to last year. Children's toy, media, and consumer products creator Mattel was a detractor in the quarter. During the quarter we had no new purchases or exits.
ALX Oncology Appoints Jeff Knight as Chief Development and Operating Officer
- Veteran biopharmaceutical and oncology leader brings more than three decades of experience across clinical development, regulatory, and operational execution
When No One Shows Up, Opportunity Does: The Office REIT Reset
The office REIT sector is bifurcating: true moats and prime locations are separating from distressed, obsolete assets. Alexandria Real Estate, Douglas Emmett, Empire State Realty Trust, and Highwoods are highlighted for durable moats and unique competitive advantages. Deep value opportunities exist where market fear has mispriced assets with irreplaceable locations, fortress balance sheets, or unique cash engines.
Mousetraps: 9 High-Yield REITs With Risky Dividends
High-yield 'mousetrap' REITs consistently underperform, with significant risk of dividend cuts and capital loss, as evidenced by recent 12-month returns lagging VNQ by over 1,000 bps. Dividend Safety scores are critical; REITs rated F face a 40% chance of a cut within 12 months, often resulting in sharp share price declines. Key danger signals include high payout ratios, weak revenues, and heavy debt loads.
Alexander’s (NYSE:ALX) vs. Four Corners Property Trust (NYSE:FCPT) Critical Analysis
Alexander's (NYSE: ALX - Get Free Report) and Four Corners Property Trust (NYSE: FCPT - Get Free Report) are both finance companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, risk and profitability. Volatility and Risk Alexander's has a beta
SG Americas Securities LLC Has $2.39 Million Position in Alexander’s, Inc. $ALX
SG Americas Securities LLC grew its stake in Alexander's, Inc. (NYSE: ALX) by 962.3% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 10,952 shares of the real estate investment trust's stock after acquiring an additional 9,921 shares during
REIT Replay: REIT Share Prices Decline In Week Ended March 13
Indexes for US equity real estate investment trusts fell further alongside the broader stock market during the week ended March 13. The Dow Jones Equity All REIT index closed the recent week down 1.52%, while the S&P 500 and Dow Jones Industrial Average fell 1.60% and 1.99%, respectively. The healthcare REIT index was the only property sector index to rise and was up 1.17%.
A Crude Awakening
U.S. equities slid to four-month lows as the escalating Iran war rattled markets, sending oil to three-year highs and interest rates higher amid tanker attacks, shipping disruptions, and intensifying strikes. Brent Crude jumped above $100 as attacks on shipping in the Strait of Hormuz and tanker explosions threatened global oil flows, fueling inflation fears and keeping investors on edge. The White House deployed emergency supply measures—including Russian crude purchases and potential strategic reserve releases—but markets remain skeptical they can offset disruptions to global energy flows.
Alexander’s (NYSE:ALX) Shares Pass Above 200 Day Moving Average – Should You Sell?
Alexander's, Inc. (NYSE: ALX - Get Free Report) shares crossed above its 200-day moving average during trading on Thursday. The stock has a 200-day moving average of $230.09 and traded as high as $251.00. Alexander's shares last traded at $244.4490, with a volume of 69,183 shares changing hands. Analyst Ratings Changes A number of analysts